Thindwa, Deus http://orcid.org/0000-0003-4845-7862
Li, Ke http://orcid.org/0000-0002-1252-670X
Cooper-Wootton, Dominic http://orcid.org/0009-0001-0080-5680
Zheng, Zhe http://orcid.org/0000-0002-1869-8529
Pitzer, Virginia E http://orcid.org/0000-0003-1015-2289
Weinberger, Daniel M http://orcid.org/0000-0003-1178-8086
Funding for this research was provided by:
National Institutes of Health (R01AI137093, R01AI137093, R01AI137093, R01AI137093, R01AI137093, R01AI137093)
Article History
Received: 24 February 2024
Accepted: 13 June 2024
First Online: 25 June 2024
Declarations
:
: These analyses used publicly available aggregate time series data at the country level and thus did not contain any data on individual human subjects. These analyses followed the guidance for the Conduct and Reporting of Modeling and Simulation Studies in the Context of Health Technology Assessment [].
: Not applicable.
: DMW has been principal investigator on grants from Pfizer and Merck to Yale University for work unrelated to this manuscript and has received consulting and/or speaking fees from Pfizer, Merck, and GSK/Affinivax. The other authors declare no competing interests.